NYSE:PTN
PALATIN TECHNOLOGIES INC
A biotech innovator pursuing novel treatments for metabolic diseases like diabetes and obesity with a focus on advancing clinical-stage drug candidates.
Key Metrics
Investment Thesis
Bull Case
Investors might consider PTN for its potential to generate a breakthrough therapy that addresses the large market opportunity in obesity and diabetes. The recent decrease in net loss suggests improving operational efficiency or successful milestone achievements in their drug development pipeline. If a key clinical trial succeeds, the value of the company could expand significantly upon future commercialization.
Bear Case
The stock is highly risky given the deep retained earnings deficit of $459.1 million and current liabilities exceeding assets by over $4 million. Revenue has stagnated or declined while losses remain substantial, indicating an unsustainable burn rate without imminent external funding. Investors should be wary of the potential for bankruptcy if the company cannot secure additional capital injections soon.
About PALATIN TECHNOLOGIES INC
Palatin Technologies (PTN) is a biotechnology firm focused on developing novel drug candidates primarily targeting Type 2 diabetes and obesity. The company operates in the specialized pharmaceutical research market, leveraging its proprietary technologies to advance clinical-stage assets. While recent revenue has remained modest at approximately $4.5 million in 2024, the firm continues to invest heavily in R&D to progress its pipeline.
Analysis
Management Discussion
Despite a reduction in the annual net loss from $29.7 million in 2024 to $17.3 million, Palatin Technologies continues to operate at a significant deficit driven by high research and development costs of nearly $15 million. The company's cash position has tightened considerably with net change in cash turning negative, relying heavily on financing activities to sustain operations. Management must successfully transition from capital raising to revenue generation to address the current liquidity constraints.
Industry Overview
The biotechnology sector is characterized by high R&D expenditures and long development cycles before products reach market. Companies in this space often report negative earnings while assets advance through clinical trials toward regulatory approval. Palatin Technologies operates within this volatile environment where success depends on the probability of clinical success and future sales potential.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $4.9M | $4.5M | $0 |
| Cost of Revenue | $0 | $97.6K | $0 |
| Gross Profit | $4.9M | $4.4M | $0 |
| Operating Expenses | $37.3M | $27.0M | $17.5M |
| Operating Income | $-32.5M | $-22.5M | $-17.5M |
| R&D | $22.6M | $22.4M | $14.9M |
| G&A | $15.3M | $12.3M | $7.8M |
| Stock-Based Comp | $1.4M | $1.9M | $1.4M |
| D&A | $288.3K | $339.1K | $258.9K |
| Other OpEx | $-608.9K | $-7.7M | $-5.2M |
| Non-Operating Income | $242.0K | $0 | $0 |
| Interest Expense | $20.0K | $17.1K | $15.0K |
| Pre-Tax Income | $-32.2M | $-22.5M | $-17.5M |
| Income Tax | $4.7M | $0 | $-152.6K |
| Continuing Ops | $-36.9M | $-22.5M | $-17.3M |
| Discontinued Ops | $9.3M | $0 | $0 |
| Net Income | $-27.5M | $-29.7M | $-17.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-27.5M | $-29.7M | $-17.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $16.3M | $9.8M | $2.9M |
| Cash & Equivalents | $11.0M | $9.5M | $2.6M |
| Marketable Securities | $3.0M | $0 | — |
| Accounts Receivable | $2.9M | $0 | — |
| Inventory | $526.0K | $0 | — |
| Prepaid Expenses | $1.9M | $242.3K | $325.7K |
| Other Current Assets | $-3.0M | $0 | $29.5K |
| Long-Term Assets | $1.6M | $972.6K | $347.5K |
| PP&E (Net) | $684.9K | $388.4K | $129.4K |
| Operating Leases | $876.1K | $527.3K | $161.2K |
| Other LT Assets | $56.9K | $56.9K | $56.9K |
| Total Assets | $17.9M | $10.7M | $3.3M |
| Current Liabilities | $15.1M | $9.7M | $8.0M |
| Accounts Payable | $4.3M | $4.1M | $7.0M |
| Current Leases | $354.1K | $380.5K | $129.8K |
| Other Current Liab | $4.0M | $990.2K | $0 |
| Long-Term Liabilities | $2.7M | $1.2M | $34.0K |
| LT Operating Leases | $544.3K | $163.8K | $34.0K |
| Other LT Liab | $2.1M | $1.0M | $0 |
| Total Liabilities | $17.8M | $10.9M | $8.0M |
| Shareholders' Equity | $134.1K | $-111.5K | $-4.8M |
| Paid-In Capital | $415.6M | $441.5M | $454.3M |
| Retained Earnings | $-415.5M | $-441.8M | $-459.1M |
| Total L&E | $17.9M | $10.7M | $3.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-27.5M | $-29.7M | $-17.3M |
| Non-Cash Adjustments | $1.5M | $1.7M | $-3.5M |
| Working Capital Changes | $-2.4M | $-3.4M | $-533.0K |
| Cash from Operations | $-28.4M | $-31.5M | $-21.3M |
| Capital Expenditures | $433.9K | $42.5K | $0 |
| Cash from Investing | $-3.4M | $12.5M | $3.1M |
| Cash from Financing | $9.9M | $20.5M | $11.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-21.9M | $1.5M | $-7.0M |
| Beginning Cash | $29.9M | $8.0M | $9.5M |
| Ending Cash | $8.0M | $9.5M | $2.6M |
Frequently Asked Questions
How does PALATIN TECHNOLOGIES INC make money?
The company's financial profile indicates a single primary revenue stream derived from product sales and licensing agreements related to its metabolic disease research, as evidenced by the absence of diversified operating segments in the current data.
What are the main risks for PTN?
The company faces substantial financial risk due to a persistent net loss of approximately $17.3 million and a negative cash flow from operations of $21.3 million. With total liabilities significantly exceeding shareholders' equity, liquidity concerns are paramount given limited cash reserves. The lack of revenue growth over the last two years highlights the high burn rate associated with developing clinical-stage biotech assets.
What is PTN's competitive advantage?
Palatin Technologies possesses a competitive edge through its proprietary technology platforms that aim to improve upon existing treatments for diabetes and obesity. The company's ability to advance assets into clinical trials without significant capital expenditures suggests efficient R&D execution. A specialized focus on unmet medical needs in metabolic disorders provides a clear path to differentiation in the crowded pharma space.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.